Decibel Therapeutics Gene Therapy Hearing Loss Treatment, DB-OTO, Receives Orphan Drug and Rare Pediatric Disease Designations from FDA
BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company’s lead gene therapy product candidate, DB-OTO, for the…
Read More
Decibel Therapeutics Announces Pricing of Initial Public Offering; Raises $127M
BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced the pricing of its initial public offering (IPO) of 7,062,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares…
Read More
Decibel Therapeutics and Catalent Partner to Develop Gene Therapy for Treatment of Congenital Hearing Loss
SOMERSET, NEW JERSEY & BOSTON, MASSACHUSSETTS — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, today announced they have signed…
Read More
Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing treatments to restore and improve hearing and balance, has announced a partnership with Invitae, a leading medical genetics company, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy.…
Read MoreDecibel Therapeutics Files for $75 Million IPO
BOSTON, MASSACHUSSETS — Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, filed on Friday with the SEC to raise up to $75 million in an initial public offering (IPO). The news was first reported by IPO investment manager Renaissance Capital. The company is the latest…
Read More
Decibel Therapeutics Announces DB-020 Granted Fast Track Designation by the FDA
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss,…
Read MoreDecibel Therapeutics Raises $82M to Advance Gene Therapies to Restore Hearing and Balance
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, today announced the closing of an oversubscribed Series D financing, which raised $82.2M. The financing was led by OrbiMed, with new investments from BlackRock Health Sciences, Casdin Capital, Janus Henderson, Samsara BioCapital and Surveyor…
Read MoreDecibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology
BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, has announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with…
Read MoreDecibel Therapeutics to Present New Findings at American Society of Gene & Cell Therapy Meeting
BOSTON, MASSACHUSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced that it will present new findings on its pipeline and platform at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which will be held virtually from May 12–15. Decibel’s…
Read MoreDecibel Therapeutics Publishes Encouraging Results from Phase 1a Clinical Trial of DB-020
BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a development-stage biotechnology company developing novel regenerative therapeutics for hearing loss and balance disorders, announced that Phase 1a trial results demonstrating the safety and tolerability of its lead candidate, DB-020, have been published in the peer-reviewed journal Investigational New Drugs. DB-020 is being developed for the prevention of cisplatin-induced hearing…
Read More